Results 241 to 250 of about 88,356 (287)

Interface‐Engineered Binary Framework Composites: Advancing Porous Materials for Precision Medicine

Advanced Materials Interfaces, EarlyView.
Binary framework composites integrate two complementary porous architectures into a unified platform, enabling multifunctional design, enhanced structural tunability, and improved physicochemical performance. By combining high surface area, ordered porosity, interfacial synergy, and versatile functionalization, these hybrid materials offer new ...
Navid Rabiee, Mohammad Rabiee, Mohammad Akrami‐Hasan‐Kohal, Sidi A. Bencherif   +3 more
wiley   +1 more source

Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. [PDF]

Mol Cancer Ther
Shia CS, Wen SN, Hsu RY, Tu JS, Chang HW, Weng HC, Yang JJ, Chiang MF, Tsao YH, Lu CH, Chen YH, Wu YC, Chen YC, Li WF, Huang TY, Lai MT.   +15 more
europepmc   +1 more source

Developing a Functional Polyelectrolyte Hybrid Layer Scaffold Coating and Evaluation of Its Performance for Interaction With Neural Cells

Advanced Materials Interfaces, EarlyView.
Polyelectrolyte scaffold coatings modified with Cu and Fe3O4 nanoparticles regulate neural stem cell behavior in vitro. Increased Fe3O4 content enhances mitochondrial activity and neuronal differentiation, whereas higher Cu levels reduce cell viability.
Anna Grzeczkowicz, Agata Lipko, Angelika Kwiatkowska, Marcin Strawski, Monika Drabik, Ludomira H. Granicka   +5 more
wiley   +1 more source

EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. [PDF]

J Clin Invest
Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y, Zhu H, Xiao S, Bian X, Wei G, Ye D, Zhu Y.   +15 more
europepmc   +1 more source

An Accessible Microfluidic Platform for the Generation of Polarized Brain Organoids

Advanced Materials Technologies, EarlyView.
This study presents an accessible double‐gradient microfluidic device that enables controlled morphogen delivery and spatially polarized differentiation in brain organoids. By integrating a pump‐free design and stable fabrication method, the platform generates dorsal–ventral neuronal asymmetry, offering a reproducible and versatile approach to model ...
Daniel Pérez‐Calixto, Manuel Alejandro Vazquez Valle, Mitzi Pérez‐Calixto, Cindy Peto‐Gutiérrez, Iván Velasco, Genaro Vázquez‐Victorio, Itzel Escobedo‐Avila   +6 more
wiley   +1 more source

Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [PDF]

Neoplasia
Almaraz-Postigo S, Redondo-Puente M, Pandiella A.   +2 more
europepmc   +1 more source

Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients. [PDF]

Clin Transl Sci
Saravanakumar A, Deng R, Dong L, Haridas S, Xia CQ, Appleman VA, Abu-Yousif AO, Piatkov K, Wang H.   +8 more
europepmc   +1 more source

Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach. [PDF]

Mol Cancer
Ianniello Z, Lu H, Quijano E, Colón-Ríos DA, Rackear M, Bommireddy V, Ludwig DL, Shen Z, Glazer PM.   +8 more
europepmc   +1 more source

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure. [PDF]

Breast
Kemik F, Şahin TK, Özçelik H, Sezer A, Başaran G, Açıkel Yüksel SD, Güney G, Yıldız İ, Er Ö, Korkmaz T, Biter S, Erdem D, Tünbekici S, Oruç A, Güren AK, Kaban K, Aykan MB, Ekinci ÖB, Deliktaş Onur İ, Kalem A, Altunok O, Seyyar M, Güney B, Akdoğan O, Yazıcı M, Majidova N, Türker S, Köylü B, Kıkılı Cİ, Demir N, Tunalı D, Laçin Ş, Tural D, Bilici A, Bayram E, Göker E, Araz M, Bayoğlu İV, Molinas Mandel N, Karadurmuş N, Çelik E, Ateş Ö, Yeşil Çınkır H, Yılmaz M, Gürsu RU, Yazıcı O, Çabuk D, Güven DC, Selçukbiricik F, Aksoy S, Gündüz Ş.   +50 more
europepmc   +1 more source

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate? [PDF]

Onco Targets Ther
Zhao Q, Luo X, Xing H, Jiang C, Ma J, Tang L.   +5 more
europepmc   +1 more source